

Title	Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings			
Summary	<p>Objective : This clinical study aims at comparing two nonmyeloablative conditioning regimens (FLU-TBI or TLI-ATG) in patients affected by hematological malignancies treated with allogeneic hematopoietic stem cell transplantation from HLA-matched donors. This will allow physicians to determine which of these conditionings is associated with the lowest incidence of acute graft-versus-host disease (GVHD) and is thus likely to improve the survival of patients.</p> <p>Primary outcome : To compare the incidence of grade II-IV acute GVHD between patients receiving FLU-TBI conditioning and patients receiving TLI-ATG conditioning.</p> <p>Disease : Hematological malignancies</p> <p>Treatment : Two nonmyeloablative conditioning regimens :</p> <ul style="list-style-type: none"> • FLU-TBI : single dose total body irradiation + chemotherapeutic drug (fludarabine) • TLI-ATG : total lymphoid irradiation (10 days) + anti-thymocyte globulins 			
Principal inclusion criteria	<ul style="list-style-type: none"> • Male or female. • Age \leq 75years. • Hematological malignancies confirmed histologically and not rapidly progressing. • Theoretical indication for a standard allo-transplant, but not feasible. • Donor related to the recipient (sibling, parent, child) or unrelated, fullfils criteria for allogeneic PBSC donation according to standard procedures. • Good performance status. • Fertile patients must use a reliable contraception method. • Informed consent given by patient or his/her guardian if of minor age. 			
Type of trial	Phase	2		
	Number of patients	100		
	Patient allocation	Patients are randomized		
	Blinding to treatment	No		
Protocol N°	BHS number	EC number	EUDRACT	ClinicalTrial.org
	TC-01	TJB0702	2007-002548-12	NCT00603954
Principal investigator and sponsor	Principal investigator		Sponsor	
	Name	Institution	CHU de Liège	
	Pr Frédéric Baron	CHU de Liège		

Participating centres	<ul style="list-style-type: none"> • AZ Maastricht, Maastricht (<u>Dr Schouten</u>) • AZ Sint-Jan, Brugge (<u>Dr Selleslag, Dr Lodewyck</u>) • CHU de Liège, Liège (<u>Dr Beguin, Dr Baron, Dr Willems</u>) • Cliniques universitaires de Mont-Godinne, Yvoir (<u>Dr Graux</u>) • H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare (<u>Dr Deeren</u>) • Hôpital de Jolimont, Haine-St-Paul (<u>Dr Straetmans</u>) • Institut Bordet, Bruxelles (<u>Dr Lewalle, Dr Firescu</u>) • UZ Antwerpen, Antwerpen (<u>Dr Berneman, Dr Schroyens</u>) • UZ Brussel, Brussel (<u>Dr Schots, Dr De Becker</u>) • UZ Gasthuisberg KUL, Leuven (<u>Dr Maertens</u>) • UZ Gent, Gent (<u>Dr Noens, Dr Kerre</u>) • ZNA Stuivenberg, Antwerpen (<u>Dr Zachée</u>) 	
Status	Start of study	January 2008
	Approximate duration	3 years (+ 2 years of follow-up) – Recruitment now completed